Statins and risk of breast cancer recurrence
Authors Sakellakis M, Akinosoglou K, Kostaki A, Spyropoulou D, Koutras A
Received 7 July 2016
Accepted for publication 30 August 2016
Published 4 November 2016 Volume 2016:8 Pages 199—205
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1
1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece
Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer.
Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence.
Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006).
Conclusion: Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups.
Keywords: statins, breast, cancer, adjuvant, recurrence
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Sakellakis M, Koutras A, Pittaka M, Kardamakis D, Kalofonou M, Kalofonos HP, Spyropoulou D
Published Date: 7 March 2016
Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H
Published Date: 29 April 2014